Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study

被引:4
作者
Zhang, Yu [1 ]
Zhu, Hao-Ping [2 ]
Fan, Jian-Xia [3 ]
Yu, Hong [4 ]
Sun, Li-Zhou [5 ]
Chen, Lian [6 ,7 ]
Chang, Qing [8 ]
Zhao, Nai-Qing [9 ]
Di, Wen [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Dept Obstet & Gynecol, Sch Med, Shanghai 200127, Peoples R China
[2] Shanghai Inst Planned Parenthood Res, Clin Trial & Training Ctr, Shanghai 200032, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Int Peace Matern & Childrens Hlth Hosp, Dept Obstet, Shanghai 200030, Peoples R China
[4] Southeast Univ, Sch Med, Zhongda Hosp, Dept Obstet & Gynecol, Nanjing 210009, Jiangsu, Peoples R China
[5] Nanjing Med Univ, Hosp 1, Dept Obstet & Gynecol, Nanjing 210029, Jiangsu, Peoples R China
[6] Sichuan Acad Med Sci, Dept Obstet & Gynecol, Chengdu 610072, Sichuan, Peoples R China
[7] Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China
[8] Third Med Univ Chinese PLA, Hosp 1, Dept Obstet & Gynecol, Chongqing 400038, Peoples R China
[9] Fudan Univ, Sch Publ Hlth, Dept Biostat & Social Med, Shanghai 200032, Peoples R China
关键词
Cervical Ripening; Intravaginal; Labor Induction; Misoprostol; Placebo; SUBSEQUENT INDUCTION; MEMBRANES; TERM;
D O I
10.4103/0366-6999.167299
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In China, no multicenter double-blinded prospective randomized controlled study on labor induction has been conducted till now. This study is to evaluate the efficacy and safety of intravaginal accurate 25-g misoprostol tablets for cervical ripening and labor induction in term pregnancy in nulliparous women. Methods: This was a double-blinded, prospective randomized controlled study including nulliparous women from 6 university hospitals across China. Subjects were randomized into misoprostol or placebo group with the sample size ratio set to 7:2. Intravaginal 25-g misoprostol or placebo was applied at an interval of 4 h (repeated up to 3 times) for labor induction. Primary outcome measures were the incidence of cumulative Bishop score increases >= 3 within 12 h or vaginal delivery within 24 h. Safety assessments included the incidences of maternal morbidity and adverse fetal/neonatal outcomes. Results: A total of 173 women for misoprostol group and 49 women for placebo were analyzed. The incidence of cumulative Bishop score increases >= 3 within 12 h or vaginal delivery within 24 h was higher in the misoprostol group than in the placebo (64.2% vs. 22.5%, relative risk [RR]: 2.9, 95% confidence interval [CI]: 1.4-6.0). The incidence of onset of labor within 24 h was significantly higher in the misoprostol group than in the placebo group (48.0% vs. 18.4%, RR: 2.6, 95% CI: 1.2-5.7); and the induction-onset of labor interval was significantly shorter in the misoprostol group (P = 0.0003). However, there were no significant differences in the median process time of vaginal labor (6.4 vs. 6.8 h; P = 0.695), incidence (39.3% vs. 49.0%, RR: 0.8, 95% CI: 0.4-1.5) and indications (P = 0.683) of cesarean section deliveries, and frequencies of maternal, fetal/neonatal adverse events between the groups. Conclusion: Intravaginal misoprostol 25 g every 4 h is efficacious and safe in labor induction and cervical ripening.
引用
收藏
页码:2736 / 2742
页数:7
相关论文
共 17 条
[1]   Labour induction with prostaglandins: a systematic review and network meta-analysis [J].
Alfirevic, Zarko ;
Keeney, Edna ;
Dowswell, Therese ;
Welton, Nicky J. ;
Dias, Sofia ;
Jones, Leanne V. ;
Navaratnam, Kate ;
Caldwell, Deborah M. .
BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
[2]  
[Anonymous], 2007, MIS REC DOS
[3]  
[Anonymous], GLOB SURV MAT PER HL
[4]  
[Anonymous], 2011, WHO recommendations for induction of labour
[5]   Misoprostol compared with prostaglandin E2 for labour induction in women at term with intact membranes and unfavourable cervix:: a systematic review [J].
Crane, J. M. G. ;
Butler, B. ;
Young, D. C. ;
Hannah, M. E. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2006, 113 (12) :1366-1376
[6]   Cesarean section in the People's Republic of China: current perspectives [J].
Feng, Xing Lin ;
Wang, Ying ;
An, Lin ;
Ronsmans, Carine .
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2014, 6 :59-74
[7]  
Hofmeyr G J., 2003, Cochrane Database Syst Rev, DOI [10.1002/14651858.CD000941, DOI 10.1002/14651858.CD000941]
[8]  
Jin F, 2009, CHIN J CLIN OBSTET G, V4, P248
[9]   Misoprostol versus expectant management in premature rupture of membranes at term [J].
Krupa, FD ;
Cecatti, JG ;
Surita, FGD ;
Milanez, HMBP ;
Parpinelli, MA .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2005, 112 (09) :1284-1290
[10]  
Martin Joyce A, 2011, Natl Vital Stat Rep, V60, P1